PURPOSE: To define the maximum-tolerated dose (MTD) and the phase II recommended dose (RD) of ecteinascidin-743 (ET-743) given as a 24-hour continuous infusion every 3 weeks to patients with treatment-refractory solid tumors. PATIENTS AND METHODS: Fifty-two patients received a total of 158 cycles of ET-743 at one of nine dose levels (DLs) ranging from 50 to 1,800 microg/m(2). RESULTS: The MTD was defined as 1,800 microg/m(2) (DL 9), and the phase II RD was 1,500 microg/m(2) (DL 8) for moderately pretreated patients with performance status (PS) 0 to 1 and good hepatobiliary function. Neutropenia and thrombocytopenia were the dose-limiting toxicities (DLTs) and were severe at the MTD (1,800 microg/m(2)) in 94% and 25% of cycles, respectively. At the RD (1,500 microg/m(2)), neutropenia and thrombocytopenia were present in 33% and 10% of cycles, respectively. Transient acute elevated transaminase levels occurred in almost all cycles and was severe in 38% of cycles. Severe toxicities and DLTs were observed in patients with poor PS or abnormal liver function or who had received a large number of previous chemotherapy regimens. Antitumor activity was observed at the three highest DLs, including three partial responses (breast cancer, osteosarcoma, and liposarcoma), and four patients (all with progressing soft tissue sarcomas) had stable disease lasting > or = 3 months. Pharmacokinetic studies were performed on all patients for at least the first cycle, giving a linear pharmacokinetic profile; this showed a relationship between area under the curve (AUC) and transaminitis grade and a clear correlation between AUC and severe hematologic toxicity likelihood. CONCLUSION: The RD for a 24-hour continuous intravenous infusion of ET-743 is 1,500 microg/m(2), with the most prevalent DLTs being hematologic. Patients with minor baseline hepatobiliary function abnormalities have a higher likelihood of severe hematologic toxicities and AUC-related DLTs, requiring dose adjustments or delays.
PURPOSE: To define the maximum-tolerated dose (MTD) and the phase II recommended dose (RD) of ecteinascidin-743 (ET-743) given as a 24-hour continuous infusion every 3 weeks to patients with treatment-refractory solid tumors. PATIENTS AND METHODS: Fifty-two patients received a total of 158 cycles of ET-743 at one of nine dose levels (DLs) ranging from 50 to 1,800 microg/m(2). RESULTS: The MTD was defined as 1,800 microg/m(2) (DL 9), and the phase II RD was 1,500 microg/m(2) (DL 8) for moderately pretreated patients with performance status (PS) 0 to 1 and good hepatobiliary function. Neutropenia and thrombocytopenia were the dose-limiting toxicities (DLTs) and were severe at the MTD (1,800 microg/m(2)) in 94% and 25% of cycles, respectively. At the RD (1,500 microg/m(2)), neutropenia and thrombocytopenia were present in 33% and 10% of cycles, respectively. Transient acute elevated transaminase levels occurred in almost all cycles and was severe in 38% of cycles. Severe toxicities and DLTs were observed in patients with poor PS or abnormal liver function or who had received a large number of previous chemotherapy regimens. Antitumor activity was observed at the three highest DLs, including three partial responses (breast cancer, osteosarcoma, and liposarcoma), and four patients (all with progressing soft tissue sarcomas) had stable disease lasting > or = 3 months. Pharmacokinetic studies were performed on all patients for at least the first cycle, giving a linear pharmacokinetic profile; this showed a relationship between area under the curve (AUC) and transaminitis grade and a clear correlation between AUC and severe hematologic toxicity likelihood. CONCLUSION: The RD for a 24-hour continuous intravenous infusion of ET-743 is 1,500 microg/m(2), with the most prevalent DLTs being hematologic. Patients with minor baseline hepatobiliary function abnormalities have a higher likelihood of severe hematologic toxicities and AUC-related DLTs, requiring dose adjustments or delays.
Authors: Lia Gore; E Rivera; M Basche; S L Moulder-Thompson; J Li; S Eppers; S Grolnic; C O'Bryant; D Cleere; Y A Elsayed; S G Eckhardt Journal: Invest New Drugs Date: 2011-09-20 Impact factor: 3.850
Authors: Axel Le Cesne; Alejandro Yovine; Jean-Yves Blay; Suzette Delaloge; Robert G Maki; Jean-Louis Misset; Pilar Frontelo; Antonio Nieto; Juhui James Jiao; George D Demetri Journal: Invest New Drugs Date: 2011-04-12 Impact factor: 3.850
Authors: Paula C Jimenez; Diego V Wilke; Paola C Branco; Anelize Bauermeister; Paula Rezende-Teixeira; Susana P Gaudêncio; Leticia V Costa-Lotufo Journal: Br J Pharmacol Date: 2019-12-23 Impact factor: 8.739
Authors: J H Beumer; N E Franke; R Tolboom; T Buckle; H Rosing; L Lopez-Lazaro; J H M Schellens; J H Beijnen; O van Tellingen Journal: Invest New Drugs Date: 2009-02-24 Impact factor: 3.850
Authors: Meredith K Chuk; Alberta Aikin; Trish Whitcomb; Brigitte C Widemann; Peter Zannikos; Eliel Bayever; Frank M Balis; Elizabeth Fox Journal: Pediatr Blood Cancer Date: 2012-07-27 Impact factor: 3.167
Authors: Juan Jose Perez-Ruixo; Peter Zannikos; Sarapee Hirankarn; Kim Stuyckens; Elizabeth A Ludwig; Arturo Soto-Matos; Luis Lopez-Lazaro; Joel S Owen Journal: Clin Pharmacokinet Date: 2007 Impact factor: 6.447